Virtual Dialogue 5: Future Research
Virtual Dialogue 5:
Future Directions for the Diagnosis and Treatment of Chondrosarcoma
The Chondrosarcoma Foundation, Inc. hosted their fifth International Forum / Virtual Dialogue on October 4, 2023 featuring the following prominent experts to address new innovations, findings, and technologies to improve the treatment of Chondrosarcoma.
How Research & Clinical Trials will Advance New Methods to Treat Chondrosarcoma
William D. Tap, MD, is a medical oncologist, and the Chief of Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York City. Dr. Tap explains that it is difficult to develop broad treatment approaches for Chondrosarcomas. However, the paradigm is shifting as nuances within these rare diseases are being better understood. As such, unique treatment opportunities are being developed internationally for patients with chondrosarcoma and other soft tissue sarcomas, According to Dr. Tap, “Broad program project areas are researching drug development and translational medicine to inform how to optimally tailor therapy to individual patients.
The Role of Interventions & Medications to Treat Chondrosarcoma
Jonathan C. Trent, M.D. is the Associate Director Clinical Research, and the Director of Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center in Miami, Fl. His work involves the use of novel preoperative and postoperative clinical trials, prospectively acquired tumor tissue, cell lines, and relationships with disciplines such as the genomics, surgical oncology, pathology, and radiology. Dr. Trent will provide an overview of medical interventions and medications including Ivosidenib / (Tibsovo), an IDH 1 biomarker inhibitor used in treating chondrosarcoma.
Neuropeptide PRP-1 and its analogs potential in the treatment of chondrosarcoma by targeting cancer stem cells.
Karina Galoian, Ph.D., is a research associate professor in the Dept of Orthopaedics at the University of Miami Leonard M. Miller School of Medicine and is Research Director of the Sarcoma Disease Site Group at Sylvester Comprehensive Cancer Center. Dr. Galoian is a Principal Investigator of Musculoskeletal Oncology Signal Transduction Laboratory. Her research is focused on neuropeptide derivatives to target specific populations of cancer stem cells and destroy them in chondrosarcomas and soft tissue sarcomas. These cells are responsible for drug and therapy resistance, cancer spread and reoccurrence.
CSPG4 as a Target for CAR-T Cell Therapy to Treat High Grade Chondrosarcoma
Joseph H. Schwab, M.D., MS, is the professor of orthopedic surgery and neurosurgery and the Director of the Center for Surgical, Artificial Intelligence for Cedars Sinai Hospital in Los Angeles, CA. Dr. Schwab combines his spine surgery and oncology training with his research interests in tumors and degenerative conditions of the spine. Dr. Schwab will address the research he conducts using Car-T therapy to treat high grade chondrosarcoma.
Critical Pathways & Target Treatment Approaches to Treat Chondrosarcoma
Andrew J. Wagner, MD, PhD, is the Deputy Chief Medical Officer and Senior Physician in the Center for Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. Dr. Wagner focuses on the treatment of patients with sarcoma and conducts research and clinical studies to identify new targets and therapeutic approaches. He has led Phase I through Phase III studies of molecularly targeted agents in sarcomas and other solid tumors. Dr. Wagner will discuss biologic pathways in chondrosarcoma and principles of clinical trial design.
A question & answer session and open discussion of the topics presented above by the presenters and participants of the Virtual Dialogue.
If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.
**A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**